Purpose/Objective: The aim of this study was the clinical validation of a customized eye tracking system (ETS) for noninvasive tumor localization and automatic motion detection in proton therapy of intraocular tumors. Materials and Methods: A prototypal ETS was tested in clinical proton therapy at Centre Antoine Lacassagne in Nice (FR). The device aims at accurate tumor localization by applying 3D infrared video-oculography technique. The cornea and pupil centers are recognized on the images acquired by two calibrated video cameras, exploiting the eye reflections produced by two infrared light sources. This allows the assessment of the 3D position and orientation of the observed eye. A custom-made calibration chessboard fitted with radiopaque beads was used to calibrate the ETS and the in-room imaging with respect to the treatment room isocenter ( fig. 1.a) . The direct linear transformation (DLT) algorithm was applied to perform geometrical calibration of the orthogonal X-Ray system using multiple radiographic images of the chessboard. Then, the concurrent localization of chessboard corners in ETS images and radiopaque beads in X-ray projections allows the calibration of the eye tracker ( fig. 1.b) . The ETS reliability in tumor localization was tested during the treatment preparation ( fig. 1 .c-d) of three eye cancer patients for proton irradiation. All of them had tantalum markers to localize the target volume. Initial patient setup error was estimated by acquiring orthogonal Xray images. Then, after applying treatment chair corrections, a further acquisition was performed for final setup verification. The markers position in the X-ray verification images were compared with those estimated by the ETS according to the detected eye position and orientation. Absolute 3D markers localization error for the entire patient cohort is shown in table 1. Moreover, when more than two markers were clearly distinguishable in X-ray projections, the imposed chair transformation is estimated and compared with the ETS observed setup correction.
Results:
The mean retro-projection error (± standard deviation) for the DLT calibration of the X-ray system was 0.06±0.03 mm. The 3D error on clips position provided by the ETS was measured below 0.75 mm, (tab. 1). Moreover, rotations and translations of clips between initial and verification X-Ray acquisition, as seen by the ETS and the XRay imaging system, are reported.
Conclusions:
The ETS prototype provides high accuracy in target localization and complies with the high standard required in proton therapy of intraocular tumors. Future activities will be focused on inter-fraction data acquisition to test the ETS accuracy and robustness.
PD-0233
Calculation of interplay effects caused by liver tumor motion during scanning proton therapy P. Purpose/Objective: Intrafraction tumor motion in scanning proton therapy may substantially distort the delivered dose distribution. These interplay effects are in particular a concern for hypofractionated treatments of liver tumors due to the large respiratory motion. Most studies of the interplay effect have been based on 4D CT scans and do not include irregular breathing. In contrast, this study use real 3D organ motions recorded during actual treatments. We establish a method to calculate the dose delivered to moving targets in scanning proton therapy by a commercial treatment planning system (TPS), and apply this method to investigate interplay effects for a number of liver SBRT patients with known tumor motion. Materials and Methods: Two three-field scanning proton plans (IMPT and single-field-optimization (SFO)) with 4mm spot spacing and a mean GTV dose of 18.75Gy per fraction were created for sixteen patients who were previously treated with three-fraction x-ray SBRT on a linear accelerator. For these patients, the 3D intra-treatment tumor motion was measured with a sampling frequency of 5-8Hz by intra-treatment x-ray imaging of implanted gold markers. The dosimetric effect of this motion on the proton plans was investigated as follows. The proton plans were dicom exported from the TPS (Eclipse, Varian Medical Systems) and manipulated by an in-house developed computer program that simulated the proton delivery using realistic spot dynamics. The program incorporated the tumor motion into the treatment plans by shifting each proton spot to its position as seen in tumor's eye view. Depth motion and variations in source-surface-distances were simulated by modifying the beam energy. The motion encoded plans were re-imported into the TPS, where dose calculation resulted in the motion including tumor dose. Treatments with both cranio-caudal and lateral beam scan direction and with 1, 2, 4, 6, and 10 (volumetric) paintings were simulated. The simulations and dose reconstruction have so far been performed for 4 of the 16 patients (3 fractions and 60 simulated treatments per patient) with relatively large and irregular tumor motion. For each treatment, the dosimetric impact of interplay effects was quantified as D 5 -D 95 for the GTV.
Results:
The figure shows the mean D 5 -D 95 as function of the number of paintings for the four simulated scenarios. For some cases, the reduction in interplay effects with increased repainting tended to be less monotonous for IMPT than for SFO, which is reflected by the larger standard variations in D 5 -D 95 for IMPT (see figure) . No systematic effect of the scan direction was observed.
Conclusions:
A method to investigate the dosimetric impact of tumor motion during proton spot scanning in a commercial TPS was developed and applied for liver SBRT treatments using patient-measured intra-treatment tumor motion. The simulations are currently being extended to all 16 patients in the motion database as well as to gated treatments 
